Plus Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2020
March 12, 2020 at 10:13 am
Share
Plus Therapeutics, Inc. Announced Executive Changes. On March 9, 2020, the Board of Directors appointed Mr. Howard Clowes to the Board, effective as of April 1, 2020. Mr. Clowes was appointed to the Board upon the recommendation of the Governance and Nominating Committee of the Board and pursuant to the bylaws of the Company. Mr. Clowes is expected to serve on the Compensation Committee and Audit Committee of the Board. Mr. Clowes served for nearly four decades as a partner at DLA Piper. The Board also appointed Dr. Robert Lenk to the Board, effective as of April 1, 2020. Dr. Lenk was appointed to the Board upon the recommendation of the Governance and Nominating Committee of the Board and pursuant to the bylaws of the Company. Dr. Lenk is President of Link Pharmaceuticals.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
PLUS THERAPEUTICS, INC. 
